<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/6E5F3390-FB4D-4CEB-8899-667E5592EE23"><gtr:id>6E5F3390-FB4D-4CEB-8899-667E5592EE23</gtr:id><gtr:name>Immunocore Limited</gtr:name><gtr:address><gtr:line1>90 PARK DRIVE , MILTON PARK</gtr:line1><gtr:city>ABINGDON</gtr:city><gtr:postCode>OX14 4RY</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6E5F3390-FB4D-4CEB-8899-667E5592EE23" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>6E5F3390-FB4D-4CEB-8899-667E5592EE23</gtr:id><gtr:name>Immunocore Limited</gtr:name><gtr:address><gtr:line1>90 PARK DRIVE , MILTON PARK</gtr:line1><gtr:city>ABINGDON</gtr:city><gtr:postCode>OX14 4RY</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>2400000.0</gtr:offerGrant><gtr:projectCost>4999393.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/3225B618-7671-4609-A790-4CBD574BB547"><gtr:id>3225B618-7671-4609-A790-4CBD574BB547</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:surname>Megit</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=101377"><gtr:id>76A62E43-4EF3-4902-B4B8-9445FA33C6CD</gtr:id><gtr:title>Clinical development of a new targeted therapy for the treatment of prostate cancer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Collaborative R&amp;D</gtr:grantCategory><gtr:grantReference>101377</gtr:grantReference><gtr:abstractText>Immunocore has developed a new class of biologic drug called ImmTACs. ImmTACs are highly novel because they recognise intracellular changes in cancerous cells and can therefore be used to treat diseases, such as prostate cancer, that are not currently ammenable to targeted biological therapies. Targeted therapies represent a significant advance over traditional chemotherapy because they selectively attack the cancer and not the rest of the body.
This project is for the development of a new ImmTAC suitable for use in prostate cancer and will culminate in testing the safety and efficacy of this targeted therapy in patients with prostate cancer.</gtr:abstractText><gtr:fund><gtr:end>2016-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2013-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2400000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">101377</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>